Revolutionizing Diagnostic Precision:  Recently our company Launch CTNT, a Next-Generation Cardiac Biomarker Solution

CTNT, a cutting-edge high-sensitivity cardiac troponin assay designed to transform the way clinicians assess and manage patients with suspected acute coronary syndrome (ACS).

CTNT represents a significant leap forward in cardiac diagnostics. Leveraging advanced monoclonal antibody technology, the assay delivers exceptional analytical sensitivity and precision, enabling the rapid detection of myocardial injury at the earliest possible stage. With a turnaround time of just [e.g., 9 minutes] and a coefficient of variation (CV) below 10% at the 99th percentile upper reference limit, CTNT empowers emergency departments and cardiology units to make faster, more confident clinical decisions.

Time is muscle when it comes to cardiac events. The pressure on emergency rooms to quickly rule in or rule out myocardial infarction is immense, With CTNT, we are providing a tool that not only meets but exceeds the latest international guidelines. Its high sensitivity allows for the exclusion of AMI with a single sample in a significant percentage of low-risk patients, potentially reducing unnecessary hospital admissions and streamlining patient flow.

Beyond its speed, CTNT is engineered for versatility and reliability. It is fully validated for use on WIZ 101 and WIZ 203 immunoassay analyzers, ensuring seamless integration into existing laboratory workflows. Key features of the CTNT assay include:

• High Sensitivity: Detects troponin levels with unparalleled accuracy to identify minor myocardial injuries.
• Broad Measuring Range: Minimizes the need for sample dilutions and re-runs, improving operational efficiency.
• Clinical Confidence: Demonstrates high diagnostic specificity, aiding in the differentiation between chronic elevation and acute events.
• Standardized Results: Aligned with international standardization efforts (IFCC) to ensure consistency in patient monitoring across different clinical settings.

The launch of CTNT reinforce that ourcompany commitment to advancing cardiovascular health through innovation. As the global burden of heart disease continues to rise, access to reliable, high-performance diagnostics is more critical than ever. CTNT equips healthcare providers with the precision necessary to initiate life-saving interventions earlier, optimize resource utilization, and ultimately improve patient outcomes.

CTNT is now available for order for global market. For more information about the CTNT assay, including technical specifications and clinical validation data, please visit our comnay website www.baysenrapidtestkit.com or contact our company sale teams.

Xiamen Baysen medical is a global medical technology company dedicated to providing advanced in-vitro diagnostic solutions. With a focus on innovation, quality, and accessibility, we develop instruments, reagents, and software that empower laboratories and healthcare professionals to deliver accurate and timely diagnoses.